Qynapse supports the investigation of Covid-19 neurological manifestations

Qynapse is developing collaborations with European and US hospitals to support the diagnosis and monitoring of neurological complications of the virus, by providing QyScore® to automatically quantify brain MRI markers in COVID-19 patients for retrospective or prospective analyses.

Qynapse releases new validation results on QyScore® performance during AAIC 2020 Conference

QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting

Qynapse is pleased to participate in the 2020 Alzheimer’s Association International Conference virtual event

Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.

Qynapse receives FDA clearance for QyScore®, a novel imaging software for central nervous system diseases

/
QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders

Qynapse exhibits at the 2019 Alzheimer’s Association International Conference (AAIC) in Los Angeles, CA

From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California

Qynapse releases new validation results of QyScore performance

QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities